Abbott Xinlay Review By Oncologic Committee Expected In Mid-September
Review of Abbott's Xinlay by FDA's Oncologic Drugs Advisory Committee for treatment of metastatic hormone-refractory prostate cancer will likely take place in mid-September
Review of Abbott's Xinlay by FDA's Oncologic Drugs Advisory Committee for treatment of metastatic hormone-refractory prostate cancer will likely take place in mid-September